Plural Oxygens Patents (Class 514/718)
-
Patent number: 7708990Abstract: The object of the present invention is to provide a composition maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time, in order to surely attain an effect of coenzyme Q, which can be expected to manifest a superior effect in maintaining health in humans and animals. By using a composition which comprises a coenzyme Q being a mixture of a reduced coenzyme Q and an oxidized coenzyme Q with the proportion of the reduced coenzyme Q to the whole coenzyme Q of more than 95% by weight, the present invention can attain a high maximum blood concentration of a coenzyme Q as well as long maintenance of high concentration of coenzyme Q in blood for a prolonged period of time, and the area under the blood concentration curve (AUC) can be expanded.Type: GrantFiled: March 22, 2005Date of Patent: May 4, 2010Assignee: Kaneka CorporationInventors: Kenji Fujii, Taizo Kawabe, Hiroshi Kubo
-
Publication number: 20100093650Abstract: A composition for inhalation, comprising at least: a) an effective amount of an antimicrobial aminoglycoside derivative or a salt thereof, and b) an effective amount of a biofilm modifier which is a macrolide derivative or a salt thereof.Type: ApplicationFiled: October 11, 2007Publication date: April 15, 2010Applicant: LABORATORIES SMB S.A.Inventors: Philippe Baudier, Francis Vanderbist, Arthur Deboeck
-
Patent number: 7674817Abstract: The antimicrobial acid-catalyzed coating composition of the invention is an acid-catalyzed coating composition formulated with at least one antimicrobial agent to provide antimicrobial activity to the coating composition and an article coated therewith.Type: GrantFiled: May 12, 2005Date of Patent: March 9, 2010Assignee: Akzo Nobel Coatings International B.V.Inventor: James H. Bray, III
-
Publication number: 20090311291Abstract: The present disclosure provides improved packaged condoms that enable the use of a large quantity of a composition inside the condom. In addition, a sufficient quantity of certain spermicidal and/or microbicidal compositions is provided for efficient inactivation of sperm and pathogens. The present disclosure also provides condoms with reduced tendency to slip or break. Compositions associated with different surfaces of the condom can be effectively segregated to their intended condom surface according to the present disclosure.Type: ApplicationFiled: July 3, 2007Publication date: December 17, 2009Applicant: REPROTECT, INC.Inventor: Thomas R. Moench
-
Publication number: 20090311354Abstract: The present invention relates to a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata or fractions thereof as an active ingredient, more precisely, a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata fruits and floral buds extracted with alcohol or alcohol aqueous solution as a solvent and active fractions isolated from the same. The extracts and fractions of the present invention inhibit lipopolysaccharide (LPS) induced nitric oxide (NO) generation significantly, have anti-inflammation activity and low cytotoxicity, and contain all of major effective components isolated from Magnolia obovata such as obovatol, honokiol and magnolol, so that they can be effectively used for the prevention and treatment of inflammatory disease.Type: ApplicationFiled: August 26, 2008Publication date: December 17, 2009Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Byoung-Mog KWON, Dong Cho HAN, Hye-Nan KIM, Young-Min HAN, So Young LEE, Dae-Seop SHIN
-
Publication number: 20090304769Abstract: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.Type: ApplicationFiled: June 4, 2007Publication date: December 10, 2009Inventors: Eric J. Kunkel, Evangelos Hytopoulos, Ivan Plavec
-
Patent number: 7579494Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.Type: GrantFiled: August 13, 2007Date of Patent: August 25, 2009Assignee: The Brigham and Women's Hospital, Inc.Inventor: Charles N. Serhan
-
Publication number: 20090202633Abstract: The present invention relates to extended release formulations comprising expectorant. More particularly, the present invention relates to extended release formulations comprising guaifenesin. The present invention also relates to a process for the preparation of extended release formulations comprising guaifenesin.Type: ApplicationFiled: January 2, 2009Publication date: August 13, 2009Inventors: Siva Ramakrishna Velaga, Saravanan Kannusamy, Madhu Kandukuri, Venkata Ram Mohan Rao Visinigiri, Nagaprasad Vishnubhotta, Sivakumaran Meenakshisunderam
-
Publication number: 20090203653Abstract: The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound, and, optionally, at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating gastrointestinal disorders; (h) treating inflammatory disorders; and (j) treating respiratory disorders. The apocynin compound may preferably be apocynin. The nitric oxide donor compound may preferably be isosorbide dinitrate and/or isosorbide mononitrate.Type: ApplicationFiled: October 3, 2005Publication date: August 13, 2009Applicant: NITROMED, INC.Inventor: David S. Garvey
-
Publication number: 20090196939Abstract: A method for antimicrobial treatment (e.g. antimicrobial treatment of food packaging and equipment) comprising applying to microbes a composition containing a diluting solvent (e.g., water), an antimicrobially-active solvent having a density different from the density of the diluting solvent, and an optional cosolvent, surfactant, or additional antimicrobial agent, wherein the amount of antimicrobially-active solvent or additional antimicrobial agent is sufficiently high and the amount of cosolvent or surfactant is sufficiently low so that the composition will provide greater than a 1-log order reduction in the population of bacteria or spores of Bacillus cereus within 10 seconds at 60° C. Preferred methods of the invention employ compositions containing an additional antimicrobial agent such as peroxyacetic acid. Compositions for use in the method can be prepared as concentrates, and used full strength or in diluted form.Type: ApplicationFiled: February 9, 2009Publication date: August 6, 2009Applicant: ECOLAB INC.Inventors: Robert D.P. Hei, Guang-jong J. Wei, David A. Halsrud, Kim R. Smith, Teresa C. Podtburg
-
Patent number: 7560491Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.Type: GrantFiled: January 19, 2007Date of Patent: July 14, 2009Assignees: Taipei Medical University, National Health Research InstitutesInventors: Jing-Ping Liou, Jang-Yang Chang
-
Patent number: 7560119Abstract: Methods of treating acne include the use of formulations including a benzoyl peroxide solution and an antioxidant.Type: GrantFiled: June 23, 2008Date of Patent: July 14, 2009Assignee: JR Chem, LLCInventors: Joseph R. Faryniarz, Jose E. Ramirez
-
Patent number: 7557145Abstract: This invention relates to the use of eugenol and/or eugenol derivatives for inhibiting the asexual propagation of fungi. This invention also relates to filter media, adhesives, building materials, building auxiliaries, textiles, pelts, paper, skins or leather, laundry detergents, cleaning compositions, rinse agents, hand washing preparations, manual dishwashing detergents, machine dishwashing detergents and preparations for finishing building materials, building auxiliaries, textiles, pelts, paper, skins or leather that contain eugenol and/or eugenol derivatives and to preparations for treating building materials, building auxiliaries, textiles, pelts, paper, skins or leather that contain eugenol and/or eugenol derivatives.Type: GrantFiled: December 16, 2005Date of Patent: July 7, 2009Assignee: Henkel Kommanditgesellschaft auf Aktien (Henkel KGAA)Inventors: Mirko Weide, Anja Schloesser, Dirk Bockmuehl, Andreas Bolte, Roland Breves
-
Patent number: 7556820Abstract: Benzoyl peroxide compositions are stabilized against decomposition by the use of antioxidants, resulting in increased shelf life of products made using the compositions. Treatment of truncal acne vulgaris with a combination of actives, namely benzoyl peroxide and salicylic acid, is provided via regimens that include applying such benzoyl peroxide compositions to an area of the body afflicted with acne, after a waiting period rinsing the benzoyl peroxide-treated area (e.g., by showering), drying the rinsed area, and then applying a topical, at least partially neutralized salicylic acid composition to the afflicted area.Type: GrantFiled: November 4, 2008Date of Patent: July 7, 2009Assignee: JR Chem, LLCInventors: José E. Ramirez, Joseph R. Faryniarz
-
Publication number: 20090155180Abstract: The present invention provides methods for identifying genes, expression regulators, receptors, protein product receptors, and proteins that may regulate rhinovirus infections. The genes identified may be used as markers for disease onset and progression and to measure efficacy of a therapeutic. The present invention also provides methods to screen agents that are capable of regulating rhinovirus infection. The present invention also provides methods of identifying therapeutic compounds that may treat various disorders by regulating the expression and activity of genes, expression regulators, receptors, protein product receptors, and proteins identified.Type: ApplicationFiled: February 28, 2008Publication date: June 18, 2009Inventors: Mary Lynn Jump, Jeffrey Warren Clymer, Begonia Y. Ho, Amy Ann Walanski, Cynthia E. Francis
-
Publication number: 20090148426Abstract: The present invention relates to a composition for life extension, comprising reduced coenzyme Q10 as an active ingredient, as well as relates to a method of extending a life span using the composition comprising reduced coenzyme Q10 as an active ingredient. In the present invention, it has been found that long-term ingestion of feed that contains reduced coenzyme Q10 enables the life span of senescence-accelerated model mice to be extended. No sign indicating toxicity is observed in the senescence-accelerated model mice that have been fed with reduced coenzyme Q10 over a long period. Based on these findings, it was found that the composition containing reduce coenzyme Q10 as an active ingredient has potential to be a composition for life extension with high safety, capable of being taken for a long period.Type: ApplicationFiled: September 21, 2006Publication date: June 11, 2009Applicant: KANEKA CORPORATIONInventors: Hideyuki Kishida, Taizuo Kawabe, Kazunori Hosoe
-
Publication number: 20090143295Abstract: Peptide-based antiacne reagents, formed by coupling a skin-binding peptide with an antiacne agent, are described. The skin-binding peptide portion of the peptide-based antiacne reagent binds strongly to the skin, thus keeping the antiacne agent coupled to the skin for a long lasting effect. Skin care compositions comprising the peptide-based antiacne reagents are also provided as well as a method of treating or preventing skin acne.Type: ApplicationFiled: November 19, 2008Publication date: June 4, 2009Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventors: JOHN P. O'BRIEN, Hong Wang, Antoinette E. Wilkins
-
Publication number: 20090142425Abstract: A physiologically active composition is claimed which comprises effective amounts of at least one compound from the group 4-O-methyldavidigenin, 4?-O-methyldavidigenin, davidigenin, elemicin, isoelemicin, herniarin, demethoxycapillarisin, in particular 6-demethoxycapillarisin and/or 6-demethoxy-3?-methoxy-capillarisin, hispiludin and 9-hydroxy-10E, 12Z, 15Z-octadecatrienoic acid, and also glycosides thereof, in particular glucosides and/or rhamnoglucosides of 4-O-methyldavidigenin and/or 4?-O-methyldavidigenin, salts and derivatives.Type: ApplicationFiled: July 21, 2005Publication date: June 4, 2009Inventors: Ralf Jager, Hans-Henning Wenk, Heike Tom Dieck, Hans Ullrich Hoppe, Roland Rabeler
-
Publication number: 20090137687Abstract: This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g., by oxidative stress) in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: June 19, 2008Publication date: May 28, 2009Applicants: OXiGENE, Inc., Baylor UniversityInventors: David Chaplin, Kevin G. Pinney, Peter Wardman, Vani P. Mocharla, Lisa K. Folkes
-
Publication number: 20090130159Abstract: It is an object of the present invention to provide a nanoparticle containing a microbicide and a biodegradable polymer, which is safe and excellent in terms of dispersion stability and has high transparency and good absorbability due to its small particle size. The present invention provides a water-dispersible nanoparticle, which comprises a microbicide and a biodegradable polymer.Type: ApplicationFiled: November 14, 2008Publication date: May 21, 2009Applicant: FUJIFILM CorporationInventor: Kazutaka OGIWARA
-
Patent number: 7524875Abstract: A modified bio-related substance, wherein at least one poly(alkylene glycol)oxy group represented by the following formula (1) is combined in a molecule: wherein R is a hydrocarbon group having 1 to 24 carbon atoms, OA1 and OA2 are each an oxyalkylene group having 2 to 4 carbon atoms, the groups represented by R are the same or different from each other in one molecule, and the groups represented by OA2 are the same or different from each other in one molecule, n and m are each average number of moles of the oxyalkylene group added, n represents 0 to 1000, and m represents 10 to 1000.Type: GrantFiled: June 2, 2005Date of Patent: April 28, 2009Assignee: NOF CorporationInventors: Ken-ichiro Nakamoto, Syunsuke Ohashi, Yuji Yamamoto, Kenji Sakanoue, Chika Itoh, Tohru Yasukohchi
-
Patent number: 7514097Abstract: (1) A tissue-covering medical material which comprises a soluble cellulose derivative having been made hardly soluble in water, which is used with a purpose of being embedded in the body or applied to the tissue, and (2) a method for producing the tissue-covering medical material as defined in (1), which comprises, as a method to make a soluble cellulose derivative hardly soluble in water, freezing and thawing an acidic solution of the soluble cellulose derivative, are provided.Type: GrantFiled: August 18, 2000Date of Patent: April 7, 2009Assignee: Denki Kagaku Kogyo Kabushiki KaishaInventors: Yasukazu Himeda, Toshihiko Umeda
-
Patent number: 7510704Abstract: This invention concerns cosmetic compositions and methods involving 4-hydroxy-3-methoxybenzyl alcohol as an active ingredient. This material is shown to be an extremely effective sub-lethal inhibitor of the metabolism of selected corynebacteria and to give significant deodorancy benefits.Type: GrantFiled: June 10, 2002Date of Patent: March 31, 2009Assignee: Unilever Home & Personal Care USA division of Conopco, Inc.Inventors: Diana Sheila Cox, Alexander Gordon James, David Taylor
-
Publication number: 20090082471Abstract: The present application describes deuterium-enriched fingolimod, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090075943Abstract: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Inventors: Kevin G. PINNEY, Madhavi Sriram
-
Publication number: 20090069443Abstract: It is intended to provide a sedative effect-imparting agent that provides excellent sedative effect with good fragrance-releasing property, and is possible to provide the excellent sedative effect immediately. The sedative effect-imparting agent according to the present invention provides excellent sedative effect immediately, since it consists of dimethoxybenzene that provides excellent sedative effect with good fragrance-releasing property.Type: ApplicationFiled: April 12, 2006Publication date: March 12, 2009Applicant: Shiseido Co., Ltd.Inventors: Keiko Mori, Yushi Terajima, Katsuyuki Yomogida, Masanori Yoshimura, Shinichiro Haze
-
Publication number: 20090011059Abstract: The present invention relates to the use of a ginger extract on its own or in combination with pharmaceutical compositions for inhibiting human drug transporters for positively influencing the oral bioavailability and pharmacokinetics of active substances.Type: ApplicationFiled: December 20, 2006Publication date: January 8, 2009Inventors: Naoki Ishiguro, Wataru Kishimoto, Thomas Ebner, Willy Roth
-
Patent number: 7473711Abstract: The present invention is directed to a class of 4-cyano-phenoxy derivatives of formula I and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.Type: GrantFiled: April 15, 2005Date of Patent: January 6, 2009Assignee: Pfizer Inc.Inventors: Lain-Yen Hu, Huangshu Lei, Daniel Y. Du, Bruce A. Lefker
-
Patent number: 7445729Abstract: Organic peroxide compositions are stabilized against decomposition by the use of antioxidants, resulting in increased shelf life of products made using the compositions.Type: GrantFiled: November 21, 2007Date of Patent: November 4, 2008Assignee: JR Chem, LLCInventors: Joseph R. Faryniarz, Jose E. Ramirez
-
Patent number: 7432305Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.Type: GrantFiled: September 15, 2006Date of Patent: October 7, 2008Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Sidney M. Hecht
-
Publication number: 20080207713Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: June 8, 2006Publication date: August 28, 2008Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Patent number: 7390431Abstract: Organic peroxide compositions are stabilized against decomposition by the use of antioxidants, resulting in increased shelf life of products made using the compositions.Type: GrantFiled: March 10, 2006Date of Patent: June 24, 2008Assignee: JR Chem, LLCInventors: Joseph R. Faryniarz, Jose E. Ramirez
-
Patent number: 7364751Abstract: The present invention provides a reduced coenzyme Q-containing solution capable of being retained more stably against oxidation, by using a reduced coenzyme Q which is hydrophobic and susceptible to oxidation and thus unstable. The aqueous solution containing a reduced coenzyme Q obtained in the present invention is a solution containing a reduced coenzyme Q and an antioxidant such as vitamin C and/or a chelating agent such as ethylenediaminetetraacetic acid.Type: GrantFiled: October 10, 2002Date of Patent: April 29, 2008Assignee: Kaneka CorporationInventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
-
Publication number: 20080085312Abstract: Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in a gradient, decreasing the side effects associated with rapidly elevated blood levels. In another embodiment, the drug is bound to an ion-exchange resin, which can be suspended in a liquid or incorporated into a matrix for delayed, sustained and/or pulsed release. Dosage unit forms may be tablets, gels, liquids, capsules, beads, microparticles, films or lozenges. Multi-phase delivery can also be achieved through the use of a kit that provides for dosage escalation. The formulations are useful in the treatment of one or more symptoms of coughs, colds, sinusitis and other respiratory illnesses.Type: ApplicationFiled: February 28, 2007Publication date: April 10, 2008Inventors: Glynn Wilson, Matthew F. Heil
-
Patent number: 7307071Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.Type: GrantFiled: December 3, 2002Date of Patent: December 11, 2007Assignee: Onyx Pharmaceuticals, IncInventors: John F. Lyons, Gideon Bollag
-
Patent number: 7268165Abstract: Antimicrobial compositions which can be used wherever disinfecting compositions are needed, such as in a hospital, healthcare industry, workplace, recreational facility, home or similar environment. The antimicrobial compositions are particularly useful as a topical application for a substrate, such as skin and can be used as a hand sanitizer or pre-surgical scrub. The compositions comprise a synergistic combination of a simple aliphatic alcohol and an activity enhancing substance, wherein the composition provides, heretofore unexpected, persistent activity against a broad range of microorganisms, including gram-negative organisms, while moisturizing the skin.Type: GrantFiled: August 20, 2004Date of Patent: September 11, 2007Assignee: Steris Inc.Inventors: Zachariah C. Greten, Nancy-Hope E. Kaiser, Daniel A. Klein
-
Patent number: 7227031Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.Type: GrantFiled: April 13, 2005Date of Patent: June 5, 2007Assignee: The Brigham and Women's Hospial, Inc.Inventor: Charles N. Serhan
-
Patent number: 7163950Abstract: According to the first aspect of the invention, a composition for reversing malarial resistance to quinolines is disclosed. The composition includes a surfactant, such as nonylphenolethoxylate (NPE) in an admixture with a pharmaceutically acceptable carrier, excipient, or diluent. According to a second aspect of the invention, a composition for the prevention or treatment of malaria is provided. The composition comprises a pharmaceutically effective amount of a quinoline in combination with a surfactant, such as NPE, for reversing malarial resistance to quinolines. According to a third aspect of the invention, a method of preventing or treating malaria in a person is provided. The method comprises administering to a patient in need thereof one or both of the compositions described above.Type: GrantFiled: November 28, 2000Date of Patent: January 16, 2007Assignee: University Health NetworkInventors: Kevin C. Cain, Ian Crandall, Jeffrey Charuk, Reinhart Reithmeier
-
Patent number: 7119123Abstract: Antimicrobially active 4-methyl-4-aryl-2-pentanols of the Formula 1 below, methods for the preparation of these compounds and their use as antimicrobial active compounds are described. Surprisingly, compounds of the Formula 1 for which: R=hydrogen, hydroxyl, alkoxy group with up to 10 C atoms, straight-chain or branched, saturated or unsaturated alkyl with up to 10 C atoms, alkylthioether group with up to 10 C atoms, the alkylthioether group being bonded to the aromatic ring via a thioether bridge, fluorine, chlorine, bromine, iodine, or alkyl with up to 10 C atoms that is interrupted by one or more oxygen and/or sulphur atoms, have proved to be antimicrobially active.Type: GrantFiled: March 3, 2004Date of Patent: October 10, 2006Assignee: Symrise GmbH & Co. KGInventors: Gerhard Schmaus, Holger Joppe
-
Patent number: 7074829Abstract: This invention relates to new antiestrogens of the general formula in which the substituents have the meanings that are explained in more detail in the description. The new compounds are a) pure antiestrogens or b) antiestrogens with partial estrogenic action (tissue-selective estrogens). Based on these properties, the new compounds are suitable for the production of pharmaceutical agents: in the case of a), for example, for the treatment of breast cancer; in the case of b), for example, for hormone replacement therapy.Type: GrantFiled: February 21, 2003Date of Patent: July 11, 2006Assignee: Schering AGInventors: Ulrich Klar, Rolf Bohlmann, Karsten Parczyk, Karl-Heinrich Fritzemeier, Monika Lessl, Rosemarie Lichtner
-
Patent number: 7056862Abstract: The invention provides an agricultural chemical enhancer and an agricultural chemical composition which are safely used for crops without any phytotoxicity, have a potency enhancing action on various agricultural chemicals and promote the growth of a plant body to be intended to be grown. The invention relates to an agricultural chemical enhancer comprising at least one type selected from a specific alcohol compound, an ether compound and an ester compound.Type: GrantFiled: December 19, 2001Date of Patent: June 6, 2006Assignee: Kao CorporationInventors: Toshio Hayashi, Tadayuki Suzuki, Kazuhiko Kurita
-
Patent number: 7045660Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: GrantFiled: March 3, 2004Date of Patent: May 16, 2006Assignee: Aventis Pharma LimitedInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
-
Patent number: 6949557Abstract: The invention relates to the use of novel anthracene based compounds for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of hydroanthracene based compounds for the inhibition and/or prevention of cancer of the colon, pancreas, prostate, lung, larynx, ovary, breast, glioblastoma, oral cavity, endothelial cells and leukemias. The agents of the invention form a distinct class, distinct from the anthracene, anthrone or anthraquinone derivatives.Type: GrantFiled: April 29, 2003Date of Patent: September 27, 2005Assignee: Dabur Research FoundationInventors: Asish Kumar Banerjee, Venkatachalam Sesha Giri, Rama Mukherjee, Kamal K. Kapoor, Gautam Desiraju, Manu Jaggi, Anu T. Singh, Sankar Kumar Dutta, Kalapatapu V. V. M. Sairam
-
Patent number: 6946484Abstract: Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.Type: GrantFiled: April 26, 2001Date of Patent: September 20, 2005Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Charles H. Graham, Jeremy P. W. Heaton, Lynne-Marie Postovit
-
Patent number: 6933320Abstract: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, platinum compounds, epidophylloptoxins, and antibiotics as the active ingredients is provided. Methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like are also provided.Type: GrantFiled: March 15, 2002Date of Patent: August 23, 2005Assignee: Aventis Pharma S. A.Inventor: Marie-Christine Bissery
-
Patent number: 6899901Abstract: The present invention is directed to a sensate composition including at least one cooling sensate, warming sensate and tingling sensate. The tingling sensate is at least one of Jambu Oleoresin and Spilanthol. The present invention is further directed to a method of using the sensate composition in a food, pharmaceutical or personal care product.Type: GrantFiled: June 17, 2003Date of Patent: May 31, 2005Assignees: Takasago International Corporation, Takasago International Corporation (USA)Inventors: Tetsuo Nakatsu, Peter J. Mazeiko, Andrew T. Lupo, Jr., Carter B. Green, Charles H. Manley, David J. Spence, Hideaki Ohta
-
Patent number: 6890567Abstract: The present invention is directed to a sensate composition including at least one cooling sensate, warming sensate and tingling sensate. The tingling sensate is at least one of Jambu Oleoresin and Spilanthol. The present invention is further directed to a method of using the sensate composition in a food, pharmaceutical or personal care product.Type: GrantFiled: July 22, 2003Date of Patent: May 10, 2005Assignees: Takasago International Corporation, Takasago International Corporation (USA)Inventors: Tetsuo Nakatsu, Peter J. Mazeiko, Andrew T. Lupo, Jr., Carter B. Green, Charles H. Manley, David J. Spence, Hideaki Ohta
-
Patent number: 6855341Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.Type: GrantFiled: November 4, 2002Date of Patent: February 15, 2005Inventor: Jeffrey B. Smith
-
Publication number: 20040259958Abstract: Antimicrobial compounds, compositions containing the same, and methods of using of the same for reducing the presence of microorganisms on a substrate or in a fluid environment comprising an antimicrobial effective carrier and at least one antimicrobial compounds including non-halogenated phenoxy and/or benzyloxy substituted phenol compounds.Type: ApplicationFiled: June 14, 2004Publication date: December 23, 2004Inventors: David Scott Harper, robert A. Coburn, Constantine Georgiades, Andre Soshinsky, Marianne D. Huntley
-
Publication number: 20040254252Abstract: Disclosed are pharmaceutical and cosmetic compositions containing as active ingredients a combination of at least one oxy group-bearing aromatic aldehyde compound and an additional cosmetically or pharmaceutically effective agent. Uses of these compositions are also disclosed.Type: ApplicationFiled: May 14, 2004Publication date: December 16, 2004Inventors: Charles R. Engles, Bryan Fuller, Brian Keith Pilcher